Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Abcellera biologics | History Defined

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program. Booth said

AbCellera Biologics Q1 Earnings Call Highlights

AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl

3 New Stocks SoftBank Is Betting Big on in 2026

3 New Stocks SoftBank Is Betting Big on in 2026

SoftBank revealed new positions in each of these three companies.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

I Asked ChatGPT’s Most Advanced Model to Find the Stocks Most Likely to 100x Over the Next 10 Years — Here’s What It Said

Here are the stocks that ChatGPT's most advanced model says are most likely to 100x over the next 10 years.

Should You Follow Insider Buying on This Biotech Penny Stock?

With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.

1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

3 AI-Driven Drug Stocks to Buy Before They Breakout

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven R&D.

inkl

Read news from The Economist, FT, and more,
with one subscription

AbCellera Biologics's Return On Capital Employed Insights

AbCellera Biologics's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, AbCellera Biologics (NASDAQ:ABCL) earned $168.57 million, a 181.2% increase from the preceding quarter. AbCellera Biologics also posted a total of $316.58 million in sales, a 127.22% increase since Q4.

What 4 Analyst Ratings Have To Say About AbCellera Biologics

What 4 Analyst Ratings Have To Say About AbCellera Biologics

Over the past 3 months, 4 analysts have published their opinion on AbCellera Biologics (NASDAQ:ABCL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Recap: AbCellera Biologics Q1 Earnings

Recap: AbCellera Biologics Q1 Earnings

AbCellera Biologics (NASDAQ:ABCL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Aehr Test Systems

Ginkgo Bioworks

AbCellera Biologics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play